The filing confirms that common stock has no expected recovery under the prepackaged plan. Monitor the bankruptcy court docket for approval of the plan and any competing bids; the stock is now trading on the Pink Limited Market under KPTIQ with speculative risk.
KPTI drugs
KPTI drug pipeline →Price Chart
Executive Summary
Karyopharm Therapeutics filed an NT 10-Q stating it cannot timely file its Q3 2026 10-Q due to the time and resource demands of its Chapter 11 bankruptcy proceedings, which began on November 2, 2026. The filing also discloses that Nasdaq suspended trading of its common stock on November 11, 2026, and that the prepackaged plan of reorganization would cancel existing equity interests with no distribution, implying a total loss for current shareholders.
Key Facts
- Company filed Chapter 11 bankruptcy petitions on November 2, 2026 (case 26-90827).
- Nasdaq suspended trading of KPTI common stock on November 11, 2026; delisting notice filed.
- Prepackaged plan cancels all existing equity interests with no distribution.
- Company cannot estimate when the Q3 10-Q will be filed.
- Limited finance/accounting personnel due to cost-cutting during bankruptcy.
- Results for Q3 2026 expected to differ significantly from Q3 2025 due to bankruptcy-related costs.
Financial Impact
Existing equity interests to be cancelled with no distribution under the prepackaged plan; market cap of $1M reflects near-total loss of value.
Risk Factors
- Complete loss of equity value per the prepackaged plan.
- Delisting from Nasdaq finalized; stock now on Pink Limited Market.
- No timeline for filing the Q3 10-Q; monthly operating reports to the court instead.
- Limited accounting personnel may delay any future filings or financial disclosures.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| NT 10-Q Filing (Primary) | 0001193125-26-460615 |
| Document: 0001193125-26-460615-index-headers.html | 0001193125-26-460615 |
| Document: 0001193125-26-460615-index.html | 0001193125-26-460615 |
| Document: 0001193125-26-460615.txt | 0001193125-26-460615 |
Track record
30 reports on KPTI
5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
- Nov 13, 20263d ago NT 10-Q Bearish 7/10 Viewing Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
- Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
- Nov 2, 202614d ago 8-K Bearish 10/10 Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
- Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
- Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers